Company / Operating Cash Flow
PROCEPT BioRobotics Corp Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$49.0M
FY2025
5-year range
-$108.0M / -$49.0M
FY2021-FY2025
Trend
+50.6%
vs FY2024
Sector context
#143 of 159
Health Care
What the data says
Among 159 Health Care companies, PROCEPT BioRobotics Corp is in the bottom 10% for operating cash flow. Improved from -$108M to -$49M over the past 2 years.
Based on SEC 10-K filings.
-$49M in FY2025.
Improved from -$108M to -$49M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 159This company -$49.0M Sector average $1.0B
▼
-104.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 50.6% year-over-year.
- Ranks #143 out of 159 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$49.0M | +50.6% |
| FY2024 | -$99.2M | +8.1% |
| FY2023 | -$108.0M | -34.4% |
| FY2022 | -$80.4M | -40.2% |
| FY2021 | -$57.3M | -18.6% |
| FY2020 | -$48.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026